Literature DB >> 17337780

Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Franklin R Toapanta1, Ted M Ross.   

Abstract

C3d is the final degradation product of the third component of complement (C3). When conjugated to an antigen, C3d enhances immune responses to the fused antigen. Therefore, this molecule has been used as an adjuvant to enhance the immune responses to various foreign and self-proteins. C3d binds to the complement receptor 2 (CR2) that is located on the surface of follicular dendritic cells (FDC), B cells, and T cells in many species. C3d stimulates antigen presentation by FCD and helps to maintain immunological B cell memory. On B cells, C3d interaction with CR2 will collect molecules such as CD19, TAPA (CD81), and Lew 13. CD19 has a long intracellular tail that triggers a signaling cascade that results in cell activation and proliferation. Furthermore, simultaneous C3d-CR2 ligation and surface immunoglobulin (sIg) by antigen, activates two signaling pathways that cross-talk and synergize to activate B cells. However, C3d can enhance antibody titers in the absence of CR2 binding, indicating CR2-independent mechanism(s) of enhancement of the immune response. This review focuses on the complexity of the C3d-CR2 interaction, the importance of this interaction for the enhancement of the immune response by C3d and its derivatives, as well as the paradoxical enhancement of the immune response in the absence of CR2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17337780     DOI: 10.1385/IR:36:1:197

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  69 in total

1.  Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).

Authors:  L Clemenza; D E Isenman
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

2.  The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens.

Authors:  A Cherukuri; P C Cheng; S K Pierce
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria.

Authors:  Elke S Bergmann-Leitner; Sandra Scheiblhofer; Richard Weiss; Elizabeth H Duncan; Wolfgang W Leitner; Defeng Chen; Evelina Angov; Farhat Khan; Jackie L Williams; David B Winter; Josef Thalhamer; Jeffrey A Lyon; George C Tsokos
Journal:  Int Immunol       Date:  2005-02-14       Impact factor: 4.823

4.  Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.

Authors:  R H Carter; M O Spycher; Y C Ng; R Hoffman; D T Fearon
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

5.  Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.

Authors:  R J Diefenbach; D E Isenman
Journal:  J Immunol       Date:  1995-03-01       Impact factor: 5.422

6.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

7.  Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway.

Authors:  Taras Lyubchenko; Joe dal Porto; John C Cambier; V Michael Holers
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

8.  DNA immunization with plasmids expressing hCGbeta-chimeras.

Authors:  Nadia Terrazzini; Sólveig Hannesdóttir; Peter J Delves; Torben Lund
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

9.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Authors:  Judy A Mitchell; Thomas D Green; Rick A Bright; Ted M Ross
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

10.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  43 in total

Review 1.  Exploring Staphylococcus aureus pathways to disease for vaccine development.

Authors:  Andrea DeDent; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Semin Immunopathol       Date:  2011-12-01       Impact factor: 9.623

Review 2.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

Review 3.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 4.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

5.  Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.

Authors:  Raymond P Brinãs; Andreas Sundgren; Padmini Sahoo; Susan Morey; Kate Rittenhouse-Olson; Greg E Wilding; Wei Deng; Joseph J Barchi
Journal:  Bioconjug Chem       Date:  2012-07-31       Impact factor: 4.774

Review 6.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

7.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

8.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

9.  Immunization of DNA vaccine encoding C3d-VP1 fusion enhanced protective immune response against foot-and-mouth disease virus.

Authors:  Huiying Fan; Tiezhu Tong; Huanchun Chen; Aizhen Guo
Journal:  Virus Genes       Date:  2007-05-12       Impact factor: 2.332

10.  Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress.

Authors:  Wei Yin; Berhane Ghebrehiwet; Babette Weksler; Ellinor I B Peerschke
Journal:  Thromb Res       Date:  2007-12-31       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.